Last reviewed · How we verify
Enoxaparin sodium (XRP4563)
Enoxaparin sodium (XRP4563) is a Low-molecular-weight heparin (LMWH) Small molecule drug developed by Sanofi. It is currently in Phase 3 development for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin sodium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboembolism prophylaxis in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.
At a glance
| Generic name | Enoxaparin sodium (XRP4563) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III enhancement) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, a natural anticoagulant, to inactivate clotting factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. The low-molecular-weight formulation provides more predictable pharmacokinetics and predominantly anti-Xa activity compared to unfractionated heparin.
Approved indications
- Thromboembolism prophylaxis in surgical patients
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome
- Prevention of thromboembolic complications in atrial fibrillation
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site reactions
- Elevated liver enzymes
Key clinical trials
- Japanese Safety and Efficacy Study of Enoxaparin in Patients With Hip Fracture Surgery (PHASE3)
- Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25) (PHASE3)
- Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoxaparin sodium (XRP4563) CI brief — competitive landscape report
- Enoxaparin sodium (XRP4563) updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Enoxaparin sodium (XRP4563)
What is Enoxaparin sodium (XRP4563)?
How does Enoxaparin sodium (XRP4563) work?
What is Enoxaparin sodium (XRP4563) used for?
Who makes Enoxaparin sodium (XRP4563)?
What drug class is Enoxaparin sodium (XRP4563) in?
What development phase is Enoxaparin sodium (XRP4563) in?
What are the side effects of Enoxaparin sodium (XRP4563)?
What does Enoxaparin sodium (XRP4563) target?
Related
- Drug class: All Low-molecular-weight heparin (LMWH) drugs
- Target: All drugs targeting Factor Xa and Factor IIa (via antithrombin III enhancement)
- Manufacturer: Sanofi — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Thromboembolism prophylaxis in surgical patients
- Indication: Drugs for Treatment of deep vein thrombosis and pulmonary embolism
- Indication: Drugs for Acute coronary syndrome
- Compare: Enoxaparin sodium (XRP4563) vs similar drugs
- Pricing: Enoxaparin sodium (XRP4563) cost, discount & access